You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

10 search results for: standard of care

interactivity

GINA Guidelines For Improved Outcomes With Effective Management of Pediatric Asthma

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

expert video

2021: EoE Year in Review

34 min

Gastroenterology

Prof. Arjan Bredenoord and Dr. Evan Dellon highlight key scientific advances made in EoE in 2021 and their potential impacts on patient care

expert video

UEGW 2024 | Something to Chew On: Exploring Biologics in EoE Management

25 min

Gastroenterology

Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care and multidimensional assessment.

IRS-ISIAN 2024 | The Importance <b>of</b> Understanding Smell Loss and Congestion in CRSwNP

expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

15 min

Rhinology

Prof. Joaquim Mullol presents on the proposed mechanisms of smell loss and nasal congestion in CRSwNP.

IRS-ISIAN 2024 | The Underappreciated Burden <b>of</b> Smell Loss and Congestion in CRSwNP

expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

5 min

Rhinology

Prof. Joaquim Mullol describes the burdens of smell loss and nasal congestion for patients with uncontrolled and/or severe CRSwNP.

IRS-ISIAN 2024 | Guideline Definitions <b>of</b> Control in CRSwNP

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

10 min

Rhinology

Prof. Peter Hellings and Prof. Eugenio De Corso discuss viewpoints on the emerging definitions of disease remission in CRSwNP.

expert video

Esophageal Dilation Does Not Impact Underlying Inflammation in EoE

1 min

Gastroenterology

Dr. Evan Dellon discusses why esophageal dilation improves symptoms but does not address the underlying histology or disease activity in EoE.

interactivity

Eosinophilic Esophagitis (EoE) Interactive Patient Case

10 min

Gastroenterology

Learn about the guidelines for diagnosis, treatment options, and criteria for treatment response in EoE through the journey of a hypothetical EoE patient.

Podcast

ADVENT On Air | Expert Discussions in Dermatology

45 min

Dermatology

Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region